

Marilyn A Huestis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8204222/publications.pdf>

Version: 2024-02-01

214
papers

12,106
citations

22153

59
h-index

37204

96
g-index

219
all docs

219
docs citations

219
times ranked

7592
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. <i>Drug and Alcohol Dependence</i> , 2014, 144, 12-41.	3.2	572
2	Cannabis Effects on Driving Skills. <i>Clinical Chemistry</i> , 2013, 59, 478-492.	3.2	476
3	Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*. <i>Journal of Analytical Toxicology</i> , 1992, 16, 276-282.	2.8	445
4	Oral Fluid Testing for Drugs of Abuse. <i>Clinical Chemistry</i> , 2009, 55, 1910-1931.	3.2	340
5	Cannabidiol Adverse Effects and Toxicity. <i>Current Neuropharmacology</i> , 2019, 17, 974-989.	2.9	244
6	Relationship of Δ^9 -Tetrahydrocannabinol Concentrations in Oral Fluid and Plasma after Controlled Administration of Smoked Cannabis. <i>Journal of Analytical Toxicology</i> , 2004, 28, 394-399.	2.8	194
7	Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ^9 -Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. <i>Clinical Chemistry</i> , 2011, 57, 66-75.	3.2	189
8	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use endpoints in clinical trials. <i>Addiction</i> , 2012, 107, 694-708.	3.3	184
9	Cannabis effects on driving lateral control with and without alcohol. <i>Drug and Alcohol Dependence</i> , 2015, 154, 25-37.	3.2	182
10	Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration. <i>Clinical Chemistry</i> , 2011, 57, 1406-1414.	3.2	149
11	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. <i>Psychopharmacology</i> , 2007, 194, 505-515.	3.1	144
12	Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. <i>Clinical Chemistry</i> , 2016, 62, 1579-1592.	3.2	139
13	Blood Cannabinoids. II. Models for the Prediction of Time of Marijuana Exposure from Plasma Concentrations of Δ^9 -Tetrahydrocannabinol (THC) and 11-nor-9-carboxy- Δ^9 -tetrahydrocannabinol (THCCOOH). <i>Journal of Analytical Toxicology</i> , 1992, 16, 283-290.	2.8	131
14	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. <i>Journal of Analytical Toxicology</i> , 2017, 41, 573-610.	2.8	128
15	Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws. <i>Clinical Chemistry</i> , 2013, 59, 519-526.	3.2	127
16	Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis. <i>Clinical Chemistry</i> , 2014, 60, 631-643.	3.2	127
17	The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study. <i>Neuropsychopharmacology</i> , 2015, 40, 1053-1063.	5.4	127
18	Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. <i>Pharmacology Biochemistry and Behavior</i> , 1990, 37, 561-565.	2.9	122

#	ARTICLE	IF	CITATIONS
19	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. <i>Clinical Chemistry</i> , 2015, 61, 850-869.	3.2	119
20	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 883-897.	3.7	116
21	Neuropharmacology of 3,4-Methylenedioxypropylvalerone (MDPV), Its Metabolites, and Related Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 93-117.	1.7	113
22	Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LC-MS/MS and Library Search. <i>Analytical Chemistry</i> , 2013, 85, 3730-3738.	6.5	108
23	Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco Exposure on Neonatal Growth. <i>Clinical Chemistry</i> , 2010, 56, 1442-1450.	3.2	106
24	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9437-9448.	3.7	106
25	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. <i>Journal of Analytical Toxicology</i> , 2015, 39, 251-261.	2.8	106
26	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. <i>Journal of Chromatography A</i> , 2015, 1397, 32-42.	3.7	103
27	Extended urinary Δ^9 -tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. <i>Drug and Alcohol Dependence</i> , 2009, 105, 24-32.	3.2	99
28	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 1763-1780.	3.7	97
29	Cannabinoid concentrations in hair from documented cannabis users. <i>Forensic Science International</i> , 2007, 169, 129-136.	2.2	95
30	New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. <i>Frontiers in Chemistry</i> , 2019, 7, 109.	3.6	95
31	Do Δ^9 -tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. <i>Addiction</i> , 2009, 104, 2041-2048.	3.3	94
32	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. <i>AAPS Journal</i> , 2015, 17, 660-677.	4.4	94
33	Urinary Elimination of 11-Nor-9-Carboxy- Δ^9 -tetrahydrocannabinol in Cannabis Users During Continuously Monitored Abstinence. <i>Journal of Analytical Toxicology</i> , 2008, 32, 562-569.	2.8	92
34	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1327, 105-117.	3.7	92
35	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1273-1283.	3.7	91
36	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. <i>Drug Metabolism Reviews</i> , 2015, 47, 124-174.	3.6	91

#	ARTICLE	IF	CITATIONS
37	Maternal smoking during pregnancy and infant stress response: Test of a prenatal programming hypothesis. <i>Psychoneuroendocrinology</i> , 2014, 48, 29-40.	2.7	88
38	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	2.5	88
39	Relating Blood Concentrations of Tetrahydrocannabinol and Metabolites to Pharmacologic Effects and Time of Marijuana Usage. <i>Therapeutic Drug Monitoring</i> , 1993, 15, 527-532.	2.0	85
40	Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ^9 -Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. <i>Journal of Analytical Toxicology</i> , 2012, 36, 405-412.	2.8	84
41	Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis. <i>Clinical Chemistry</i> , 2013, 59, 1780-1789.	3.2	84
42	Current knowledge on cannabinoids in oral fluid. <i>Drug Testing and Analysis</i> , 2014, 6, 88-111.	2.6	84
43	Linear pharmacokinetics of 3,4-methylenedioxypropylvalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , 2016, 21, 339-347.	2.6	83
44	First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry. <i>Clinical Chemistry</i> , 2013, 59, 1638-1648.	3.2	82
45	Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 239-253.	4.7	81
46	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. <i>Drug Testing and Analysis</i> , 2017, 9, 905-915.	2.6	80
47	Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results. <i>Journal of Analytical Toxicology</i> , 2019, 43, 415-443.	2.8	78
48	Cannabis effects on driving longitudinal control with and without alcohol. <i>Journal of Applied Toxicology</i> , 2016, 36, 1418-1429.	2.8	77
49	Estimating the Time of Last Cannabis Use from Plasma Δ^9 -Tetrahydrocannabinol and 11-nor-9-Carboxy- Δ^9 -Tetrahydrocannabinol Concentrations. <i>Clinical Chemistry</i> , 2005, 51, 2289-2295.	3.2	76
50	Simultaneous GC-EI-MS Determination of Δ^9 -Tetrahydrocannabinol, 11-Hydroxy- Δ^9 -Tetrahydrocannabinol, and 11-nor-9-Carboxy- Δ^9 -Tetrahydrocannabinol in Human Urine Following Tandem Enzyme-Alkaline Hydrolysis. <i>Journal of Analytical Toxicology</i> , 2007, 31, 477-485.	2.8	75
51	First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2013, 15, 1091-1098.	4.4	75
52	Urinary Excretion Half-Life of 11-Nor-9-carboxy- Δ^9 -tetrahydrocannabinol in Humans. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 570-576.	2.0	71
53	Pharmacokinetics of Cocaine and Metabolites in Human Oral Fluid and Correlation With Plasma Concentrations After Controlled Administration. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 628-637.	2.0	70
54	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2016, 18, 1489-1499.	4.4	69

#	ARTICLE	IF	CITATIONS
55	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. <i>Addiction</i> , 2011, 106, 499-506.	3.3	68
56	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. <i>Clinical Chemistry</i> , 2016, 62, 157-169.	3.2	65
57	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. <i>Drug and Alcohol Dependence</i> , 2017, 175, 67-76.	3.2	65
58	Cannabis in Sport. <i>Sports Medicine</i> , 2011, 41, 949-966.	6.5	64
59	Tolerance to Effects of High-Dose Oral δ^9 -Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. <i>Journal of Analytical Toxicology</i> , 2013, 37, 11-16.	2.8	64
60	Identifying New Cannabis Use with Urine Creatinine-Normalized THCCOOH Concentrations and Time Intervals Between Specimen Collections. <i>Journal of Analytical Toxicology</i> , 2009, 33, 185-189.	2.8	62
61	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. <i>Drug Metabolism Reviews</i> , 2016, 48, 237-265.	3.6	60
62	Cannabinoid Disposition in Oral Fluid after Controlled Smoked Cannabis. <i>Clinical Chemistry</i> , 2012, 58, 748-756.	3.2	59
63	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1977-1990.	3.7	58
64	The Potential Role of Oral Fluid in Antidoping Testing. <i>Clinical Chemistry</i> , 2014, 60, 307-322.	3.2	58
65	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2015, 33, 295-310.	2.4	58
66	Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2012, 413, 1839-1847.	1.1	57
67	Cannabinoid Stability in Authentic Oral Fluid after Controlled Cannabis Smoking. <i>Clinical Chemistry</i> , 2012, 58, 1101-1109.	3.2	56
68	Metabolic profiling of new synthetic cannabinoids AMB and 5F δ^9 AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 1067-1078.	1.5	56
69	Comparative Pharmacokinetics of δ^9 -Tetrahydrocannabinol in Adolescent and Adult Male Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 151-160.	2.5	56
70	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. <i>Drug Testing and Analysis</i> , 2014, 6, 728-738.	2.6	54
71	Intra- and Intersubject Whole Blood/Plasma Cannabinoid Ratios Determined by 2-Dimensional, Electron Impact GC-MS with Cryofocusing. <i>Clinical Chemistry</i> , 2009, 55, 1188-1195.	3.2	53
72	Excretion of δ^9 -tetrahydrocannabinol in sweat. <i>Forensic Science International</i> , 2008, 174, 173-177.	2.2	52

#	ARTICLE	IF	CITATIONS
73	Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. <i>Nicotine and Tobacco Research</i> , 2010, 12, 658-664.	2.6	52
74	Effect of Blood Collection Time on Measured δ^9 -Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. <i>Clinical Chemistry</i> , 2016, 62, 367-377.	3.2	51
75	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. <i>AAPS Journal</i> , 2016, 18, 455-464.	4.4	50
76	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. <i>Accident Analysis and Prevention</i> , 2016, 92, 219-229.	5.7	49
77	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6461-6471.	3.7	49
78	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
79	Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. <i>Clinica Chimica Acta</i> , 2012, 413, 765-770.	1.1	48
80	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1453, 34-42.	3.7	48
81	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. <i>Clinical Chemistry</i> , 2017, 63, 1008-1021.	3.2	48
82	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71.	4.8	48
83	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 8451-8461.	3.7	47
84	Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. <i>Trends in Molecular Medicine</i> , 2018, 24, 156-172.	6.7	47
85	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. <i>Forensic Science International</i> , 2014, 241, 27-34.	2.2	46
86	4-Methoxy- δ^9 -PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2016, 34, 61-75.	2.4	46
87	In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis. <i>Clinical Chemistry</i> , 2013, 59, 1108-1117.	3.2	45
88	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2015, 7, 684-694.	2.6	45
89	On-Site Test for Cannabinoids in Oral Fluid. <i>Clinical Chemistry</i> , 2012, 58, 1418-1425.	3.2	44
90	<i>In vitro</i> , <i>in vivo</i> and <i>in silico</i> metabolic profiling of δ^9 -pyrrolidinopentiothiophenone, a novel thiophene stimulant. <i>Bioanalysis</i> , 2016, 8, 65-82.	1.5	44

#	ARTICLE	IF	CITATIONS
91	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting δ^9 -Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. <i>Clinical Chemistry</i> , 2017, 63, 647-662.	3.2	44
92	Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107641.	3.2	44
93	A Review of Synthetic Cathinone-Related Fatalities From 2017 to 2020. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 52-68.	2.0	44
94	Excretion of Methamphetamine and Amphetamine in Human Sweat Following Controlled Oral Methamphetamine Administration. <i>Clinical Chemistry</i> , 2008, 54, 172-180.	3.2	43
95	Disposition of Cannabinoids in Oral Fluid after Controlled Around-the-Clock Oral THC Administration. <i>Clinical Chemistry</i> , 2010, 56, 1261-1269.	3.2	43
96	Adolescent cortical thickness pre- and post marijuana and alcohol initiation. <i>Neurotoxicology and Teratology</i> , 2016, 57, 20-29.	2.4	43
97	Epigenetic Regulation of Placental <i>NR3C1</i> : Mechanism Underlying Prenatal Programming of Infant Neurobehavior by Maternal Smoking?. <i>Child Development</i> , 2016, 87, 49-60.	3.0	43
98	25-OH and 25-I metabolite studies in human hepatocytes, <i>in vivo</i> mouse and human urine with high-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2017, 9, 680-698.	2.6	43
99	Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC-MS-MS. <i>Journal of Analytical Toxicology</i> , 2020, 44, 697-707.	2.8	43
100	Identification of Prenatal Amphetamines Exposure by Maternal Interview and Meconium Toxicology in the Infant Development, Environment and Lifestyle (IDEAL) Study. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 769-775.	2.0	41
101	Predictive model accuracy in estimating last δ^9 -tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. <i>Drug and Alcohol Dependence</i> , 2012, 125, 313-319.	3.2	41
102	Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. <i>Clinical Chemistry</i> , 2020, 66, 888-914.	3.2	41
103	Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 540-544.	2.0	40
104	Postmortem redistribution of δ^9 -tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). <i>Forensic Science International</i> , 2011, 212, 247-251.	2.2	40
105	Changes in Smoking Patterns During Pregnancy. <i>Substance Use and Misuse</i> , 2013, 48, 513-522.	1.4	40
106	3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. <i>Analytica Chimica Acta</i> , 2014, 827, 54-63.	5.4	40
107	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and <i>Ad libitum</i> Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015, 39, 580-587.	2.8	40
108	High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, <i>N</i> -(adamantan-1-yl)-5-fluoropentyl-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. <i>Drug Testing and Analysis</i> , 2015, 7, 187-198.	2.6	40

#	ARTICLE	IF	CITATIONS
109	THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis". <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 682-689.	2.3	40
110	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2017, 15, 682-691.	2.9	39
111	Simultaneous quantification of δ^9 -tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography "high resolution mass spectrometry. <i>Journal of Chromatography A</i> , 2013, 1297, 123-130.	3.7	38
112	Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC-Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers?. <i>Clinical Chemistry</i> , 2014, 60, 361-372.	3.2	38
113	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>Journal of Pain Research</i> , 2016, Volume 9, 587-598.	2.0	38
114	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid "blood cannabinoid relationships. <i>Drug Testing and Analysis</i> , 2016, 8, 690-701.	2.6	38
115	Urinary Cannabinoid Detection Times after Controlled Oral Administration of δ^9 -Tetrahydrocannabinol to Humans. <i>Clinical Chemistry</i> , 2003, 49, 1114-1124.	3.2	37
116	Anger, Hostility, and Aggression as Predictors of Persistent Smoking During Pregnancy. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 926-932.	1.0	35
117	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 4679-4689.	3.7	35
118	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4117-4128.	3.7	35
119	Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. <i>Drug Testing and Analysis</i> , 2015, 7, 483-493.	2.6	35
120	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 4845-4856.	3.7	34
121	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 68-75.	3.2	34
122	Oral Fluid and Plasma Cannabinoid Ratios after Around-the-Clock Controlled Oral δ^9 -Tetrahydrocannabinol Administration. <i>Clinical Chemistry</i> , 2011, 57, 1597-1606.	3.2	33
123	Metabolic characterization of AH7921, a synthetic opioid designer drug: <i>in vitro</i> metabolic stability assessment and metabolite identification, evaluation of <i>in silico</i> prediction, and <i>in vivo</i> confirmation. <i>Drug Testing and Analysis</i> , 2016, 8, 779-791.	2.6	33
124	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. <i>Drug Testing and Analysis</i> , 2016, 8, 682-689.	2.6	33
125	Maternal Buprenorphine Maintenance and Lactation. <i>Journal of Human Lactation</i> , 2016, 32, 675-681.	1.6	31
126	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). <i>Forensic Toxicology</i> , 2017, 35, 20-32.	2.4	31

#	ARTICLE	IF	CITATIONS
127	Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. <i>Clinical Chemistry</i> , 2017, 63, 1564-1569.	3.2	31
128	Development and validation of LC-MS/MS and GC-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. <i>Journal of Mass Spectrometry</i> , 2011, 46, 603-614.	1.6	30
129	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. <i>Drug Testing and Analysis</i> , 2014, 6, 1002-1010.	2.6	30
130	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 1945-1955.	3.7	30
131	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1957-1965.	3.7	29
132	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. <i>Drug and Alcohol Dependence</i> , 2013, 130, 68-76.	3.2	29
133	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. <i>Drug Testing and Analysis</i> , 2015, 7, 467-474.	2.6	29
134	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. <i>Journal of Applied Toxicology</i> , 2017, 37, 922-932.	2.8	29
135	Toxicology and Analysis of Psychoactive Tryptamines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9279.	4.1	29
136	A Rapid Reusable Fiber Optic Biosensor for Detecting Cocaine Metabolites in Urine. <i>Journal of Analytical Toxicology</i> , 1999, 23, 460-467.	2.8	28
137	Meconium Nicotine and Metabolites by Liquid Chromatography-Tandem Mass Spectrometry: Differentiation of Passive and Nonexposure and Correlation with Neonatal Outcome Measures. <i>Clinical Chemistry</i> , 2008, 54, 2018-2027.	3.2	28
138	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 423-34.	2.3	28
139	Smoking in Pregnancy and Fetal Growth: The Case for More Intensive Assessment. <i>Nicotine and Tobacco Research</i> , 2017, 19, 525-531.	2.6	28
140	Drug exposure during pregnancy: analytical methods and toxicological findings. <i>Bioanalysis</i> , 2018, 10, 587-606.	1.5	28
141	Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 673-681.	2.3	28
142	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173059.	2.9	28
143	Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 599-607.	3.7	27
144	Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. <i>Drug Testing and Analysis</i> , 2017, 9, 143-147.	2.6	27

#	ARTICLE	IF	CITATIONS
145	Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. <i>Neurotoxicology and Teratology</i> , 2018, 68, 47-56.	2.4	27
146	Effect of hydrolysis on identifying prenatal cannabis exposure. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 2335-2347.	3.7	26
147	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 6213-6223.	3.7	25
148	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 785-792.	3.7	25
149	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. <i>AAPS Journal</i> , 2017, 19, 568-577.	4.4	25
150	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 7269-7279.	3.7	24
151	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. <i>Bioanalysis</i> , 2015, 7, 2041-2056.	1.5	24
152	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. <i>Forensic Science International</i> , 2016, 260, 95-101.	2.2	23
153	Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. <i>Psychopharmacology</i> , 2017, 234, 3431-3442.	3.1	23
154	Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. <i>Bioanalysis</i> , 2014, 6, 1187-1200.	1.5	22
155	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. <i>Drug Testing and Analysis</i> , 2015, 7, 114-120.	2.6	22
156	Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells. <i>Archives of Toxicology</i> , 2017, 91, 3633-3643.	4.2	22
157	Optimization of recombinant β -glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 518-529.	2.6	22
158	Prenatal tobacco exposure and infant stress reactivity: Role of child sex and maternal behavior. <i>Developmental Psychobiology</i> , 2015, 57, 212-225.	1.6	21
159	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. <i>Forensic Toxicology</i> , 2016, 34, 256-267.	2.4	21
160	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 27-35.	2.8	21
161	11-Nor-9-carboxy- Δ^9 -tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 6019-6027.	3.7	20
162	Validation of an ELISA Synthetic Cannabinoids Urine Assay. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 661-669.	2.0	20

#	ARTICLE	IF	CITATIONS
163	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 4639-4648.	3.7	20
164	Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2020, 1624, 461241.	3.7	20
165	Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. <i>Bioanalysis</i> , 2014, 6, 1471-1485.	1.5	19
166	Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior. <i>Neurotoxicology and Teratology</i> , 2018, 70, 28-39.	2.4	19
167	Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003-2015). <i>Neurotoxicology and Teratology</i> , 2018, 68, 97-106.	2.4	19
168	Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 194-204.	2.0	19
169	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. <i>Drug and Alcohol Dependence</i> , 2016, 163, 116-125.	3.2	18
170	Acute and residual mood and cognitive performance of young adults following smoked cannabis. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 194, 172937.	2.9	18
171	Prenatal Tobacco and Cannabis Exposure: Associations with Cortisol Reactivity in Early School Age Children. <i>International Journal of Behavioral Medicine</i> , 2020, 27, 343-356.	1.7	18
172	Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. <i>Drug Testing and Analysis</i> , 2021, 13, 539-549.	2.6	18
173	Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 218-224.	2.0	17
174	Cannabis-Impaired Driving: A Public Health and Safety Concern. <i>Clinical Chemistry</i> , 2015, 61, 1223-1225.	3.2	17
175	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 543-550.	2.5	17
176	Correlation of creatinine and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. <i>Drug Testing and Analysis</i> , 2019, 11, 968-975.	2.6	17
177	Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108962.	3.2	17
178	Method validation of the biochip array technology for synthetic cannabinoids detection in urine. <i>Bioanalysis</i> , 2014, 6, 2919-2930.	1.5	16
179	Identifying Methamphetamine Exposure in Children. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 823-830.	2.0	15
180	Prenatal Risk and Infant Regulation: Indirect Pathways via Fetal Growth and Maternal Prenatal Stress and Anger. <i>Child Development</i> , 2018, 89, e123-e137.	3.0	15

#	ARTICLE	IF	CITATIONS
181	Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 205-221.	2.0	15
182	Combined effect of alcohol and cannabis on simulated driving. <i>Psychopharmacology</i> , 2022, 239, 1263-1277.	3.1	15
183	Quantification of 11-Nor-9-Carboxy- δ^9 -Tetrahydrocannabinol in Human Oral Fluid by Gas Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 225-233.	2.0	14
184	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. <i>Forensic Toxicology</i> , 2015, 33, 260-278.	2.4	14
185	On-site oral fluid δ^9 -tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. <i>Forensic Toxicology</i> , 2017, 35, 133-145.	2.4	13
186	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 108-117.	1.7	13
187	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020, 44, 651-660.	2.8	12
188	Piezoresistive Microcantilevers-Based Cocaine Biosensors. <i>Sensor Letters</i> , 2012, 10, 850-855.	0.4	12
189	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. <i>Clinical Chemistry</i> , 2017, 63, 1753-1763.	3.2	11
190	Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood. <i>Neurotoxicology and Teratology</i> , 2018, 69, 39-48.	2.4	11
191	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2018, 36, 304-312.	2.4	10
192	Identification of δ^9 -tetrahydrocannabinol (THC) impairment using functional brain imaging. <i>Neuropsychopharmacology</i> , 2022, 47, 944-952.	5.4	10
193	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. <i>Forensic Toxicology</i> , 2015, 33, 202-212.	2.4	9
194	Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. <i>Neurotoxicology and Teratology</i> , 2016, 57, 87-94.	2.4	9
195	Prenatal exposure to tobacco and marijuana and child autonomic regulation and reactivity: An analysis of indirect pathways via maternal psychopathology and parenting. <i>Developmental Psychobiology</i> , 2019, 61, 1022-1034.	1.6	9
196	Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges. <i>Current Addiction Reports</i> , 2019, 6, 429-436.	3.4	9
197	Prenatal tobacco and marijuana co-use: Sex-specific influences on infant cortisol stress response. <i>Neurotoxicology and Teratology</i> , 2020, 79, 106882.	2.4	9
198	Pyrrrolidinyl Synthetic Cathinones α -PHP and 4F- α -PVP Metabolite Profiling Using Human Hepatocyte Incubations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 230.	4.1	9

#	ARTICLE	IF	CITATIONS
199	Impact of cannabis and low alcohol concentration on divided attention tasks during driving. <i>Traffic Injury Prevention</i> , 2020, 21, S123-S129.	1.4	8
200	Effects of fetal tobacco exposure on focused attention in infancy. , 2016, 45, 1-10.		7
201	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2017, 35, 252-262.	2.4	7
202	Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 546-558.	1.8	7
203	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1451, 97-106.	3.7	6
204	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. <i>Forensic Toxicology</i> , 2018, 36, 102-112.	2.4	6
205	Substance use onset in high-risk 9-13-year-olds in the ABCD study. <i>Neurotoxicology and Teratology</i> , 2022, 91, 107090.	2.4	6
206	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 118, 110570.	4.8	6
207	Urine Mescaline Screening With a Biochip Array Immunoassay and Quantification by Gas Chromatography-Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 805-811.	2.0	5
208	Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1203-1212.	4.7	5
209	Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 209-215.	2.5	3
210	Urinary clearance of 11-nor-9-carboxy- Δ^9 -tetrahydrocannabinol: A detailed pharmacokinetic analysis. <i>Drug Testing and Analysis</i> , 2022, 14, 1368-1376.	2.6	3
211	The effect of prenatal adversity on externalizing behaviors at 24 months of age in a high-risk sample: Maternal sensitivity as a moderator. <i>Infant Mental Health Journal</i> , 2020, 41, 530-542.	1.8	2
212	Reprint of "Adolescent cortical thickness pre- and post marijuana and alcohol initiation". <i>Neurotoxicology and Teratology</i> , 2016, 58, 78-87.	2.4	1
213	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2016, , .	2.9	1
214	Cannabinoids Pharmacology, Abuse, and Addiction. , 2016, , 1-27.		0